文献速递乳腺癌放疗

早期腔面型乳腺癌术前立体定向体部放疗的系统综述与荟萃分析

Preoperative stereotactic body radiotherapy for early-stage luminal breast cancer: a systematic review and meta-analysis (PRELUMEN).
PubMed 文献 · Radiother Oncol · 2026-08-16

BACKGROUND AND PURPOSE: Preoperative stereotactic body radiotherapy (SBRT) has emerged as a precision locoregional strategy for early luminal breast cancer, yet no quantitative meta-analysis exists in this subtype.…

要点

  • 术前SBRT在早期腔面型乳腺癌中汇总pCR率为21.4%(95%CI 12.1-35.1%)。
  • 放疗至手术间隔是pCR的唯一显著预测因素(每周β=+0.045,p<0.001)。
  • 晚期≥3级毒性5.9%,美容优良率88.3%,安全性可接受。

核心结论

  • 术前SBRT在早期腔面型乳腺癌中达到有临床意义的pCR率,毒性可接受且美容效果保留。
  • 放疗至手术间隔是病理反应的主要可干预预测因素,值得在前瞻性随机试验中优化。

研究设计与样本

  • 遵循PRISMA 2020指南的系统综述与荟萃分析,纳入术前SBRT治疗临床T1-T2 N0-N1腔面型(ER阳性、HER2阴性)乳腺癌的前瞻性试验。
  • 采用随机效应模型(REML估计)对logit转换比例进行合并,并用单因素荟萃回归分析协变量。

主要发现

  • 8项试验(N=277)报告pCR数据,汇总pCR率为21.4%(95%CI 12.1-35.1%;I2=77.0%)。
  • 放疗至手术间隔是pCR的唯一显著预测因素(每周β=+0.045;p<0.001;R2=98.9%)。
  • BED_4、分次方案和技术与pCR无独立关联。
  • 汇总晚期≥3级毒性为5.9%(95%CI 3.7-9.1%)。
  • 美容结局优良或良好者占88.3%(95%CI 79.4-93.6%)。

关键数值与推荐

  • 汇总pCR率21.4%(95%CI 12.1-35.1%;I2=77.0%),基于8项试验277例患者。
  • 放疗至手术间隔每延长一周与pCR相关(β=+0.045;p<0.001;R2=98.9%)。
  • 汇总晚期≥3级毒性5.9%(95%CI 3.7-9.1%)。
  • 美容优良或良好率88.3%(95%CI 79.4-93.6%)。

临床怎么用

  • 术前SBRT可作为早期腔面型乳腺癌的精准局部区域策略,pCR率有临床意义且安全性可接受。
  • 放疗至手术间隔是可控因素,临床规划时应关注并优化该间隔以改善病理反应。
  • 美容结局优良率高,支持该方案在保留美容效果方面的应用价值。

局限性

  • 纳入研究均为前瞻性试验但非随机对照,证据等级受限。
  • pCR分析存在高度异质性(I2=77.0%)。
  • 部分结局指标(如pCR)仅8项试验277例患者报告,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Preoperative stereotactic body radiotherapy (SBRT) has emerged as a precision locoregional strategy for early luminal breast cancer, yet no quantitative meta-analysis exists in this subtype. We aimed to estimate the pooled pathological complete response (pCR) rate, identify its predictors through meta-regression, and characterise safety and cosmetic outcomes. MATERIALS AND METHODS: A systematic review and meta-analysis of prospective trials of preoperative SBRT in patients with clinical stage T1-T2 N0-N1 luminal (ER-positive, HER2-negative) breast cancer was conducted following PRISMA 2020 guidelines. Random-effects models with REML estimation were fitted on logit-transformed proportions. Univariable meta-regression analyses examined absorbed dose (BED_4), irradiation-to-surgery interval, fractionation, technique, and biological tumor characteristics as covariates. RESULTS: Eleven prospective studies (428 patients) were included. Eight trials (N = 277) reported pCR data, yielding a pooled pCR rate of 21.4 % (95 % CI: 12.1-35.1 %; I2 = 77.0 %). The irradiation-to-surgery interval was the sole statistically significant predictor of pCR (β = +0.045 per week; p < 0.001; R2 = 98.9 %), whilst BED_4, fractionation, and technique showed no independent association. Pooled late grade ≥ 3 toxicity was 5.9 % (95 % CI: 3.7-9.1 %) and excellent or good cosmesis was achieved in 88.3 % of patients (95 % CI: 79.4-93.6 %). CONCLUSION: Preoperative SBRT achieves a clinically meaningful pCR rate in early luminal breast cancer, with acceptable toxicity and preserved cosmesis. The irradiation-to-surgery interval is the dominant modifiable predictor of pathological response. Randomized trials prospectively optimizing this interval in the luminal subtype are warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Viani GA, Arruda CV, Hamamura AC, et al. Preoperative stereotactic body radiotherapy for early-stage luminal breast cancer: a systematic review and meta-analysis (PRELUMEN). Radiother Oncol. 2026. PMID: 42603618. doi:10.1016/j.radonc.2026.111743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。